Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s second “complete response” letter for Transcept Pharmaceuticals’s Intermezzo continues the strict scrutiny the agency has given recent candidates for sleep maintenance insomnia indications.

Related Content

Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
Transcept's NDA Intermission For Insomnia Drug Intermezzo Set To End In First Quarter
Somaxon Sleep Aid Silenor Not Effective, FDA Says
Somaxon Sleep Aid Silenor Not Effective, FDA Says





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts